Selected article for: "acute respiratory failure and low risk infection"
Author: Faraone, Antonio; Beltrame, Chiara; Crociani, Andrea; Carrai, Paolo; Lovicu, Elena; Filetti, Simona; Sbaragli, Serena; Alessi, Chiara; Cameron Smith, Michela; Angotti, Chiara; Fortini, Alberto
Title: Effectiveness and safety of noninvasive positive pressure ventilation in the treatment of COVID-19-associated acute hypoxemic respiratory failure: a single center, non-ICU setting experience
  • Cord-id: 1bmi4mm2
  • Document date: 2020_11_22
    • ID: 1bmi4mm2
    Snippet: The role of noninvasive positive pressure ventilation (NIPPV) in COVID-19 patients with acute hypoxemic respiratory failure (AHRF) is uncertain, as no direct evidence exists to support NIPPV use in such patients. We retrospectively assessed the effectiveness and safety of NIPPV in a cohort of COVID-19 patients consecutively admitted to the COVID-19 general wards of a medium-size Italian hospital, from March 6 to May 7, 2020. Healthcare workers (HCWs) caring for COVID-19 patients were monitored,
    Document: The role of noninvasive positive pressure ventilation (NIPPV) in COVID-19 patients with acute hypoxemic respiratory failure (AHRF) is uncertain, as no direct evidence exists to support NIPPV use in such patients. We retrospectively assessed the effectiveness and safety of NIPPV in a cohort of COVID-19 patients consecutively admitted to the COVID-19 general wards of a medium-size Italian hospital, from March 6 to May 7, 2020. Healthcare workers (HCWs) caring for COVID-19 patients were monitored, undergoing nasopharyngeal swab for SARS-CoV-2 in case of onset of COVID-19 symptoms, and periodic SARS-CoV-2 screening serology. Overall, 50 patients (mean age 74.6 years) received NIPPV, of which 22 (44%) were successfully weaned, avoiding endotracheal intubation (ETI) and AHRF-related death. Due to limited life expectancy, 25 (50%) of 50 NIPPV-treated patients received a “do not intubate” (DNI) order. Among these, only 6 (24%) were weaned from NIPPV. Of the remaining 25 NIPPV-treated patients without treatment limitations, 16 (64%) were successfully weaned, 9 (36%) underwent delayed ETI and, of these, 3 (33.3%) died. NIPPV success was predicted by the use of corticosteroids (OR 15.4, CI 1.79–132.57, p 0.013) and the increase in the PaO(2)/FiO(2) ratio measured 24–48 h after NIPPV initiation (OR 1.02, CI 1–1.03, p 0.015), while it was inversely correlated with the presence of a DNI order (OR 0.03, CI 0.001–0.57, p 0.020). During the study period, 2 of 124 (1.6%) HCWs caring for COVID-19 patients were diagnosed with SARS-CoV-2 infection. Apart from patients with limited life expectancy, NIPPV was effective in a substantially high percentage of patients with COVID-19-associated AHRF. The risk of SARS-CoV-2 infection among HCWs was low.

    Search related documents:
    Co phrase search for related documents
    • activity month and logistic regression: 1, 2, 3, 4, 5, 6, 7
    • activity period and acute care: 1
    • activity period and acute care hospital: 1
    • activity period and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • activity period and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • activity period and logistic regression model: 1
    • activity period and low molecular: 1
    • activity period and low molecular weight: 1
    • activity termination and acute respiratory syndrome: 1
    • acute ahrf hypoxemic respiratory failure and logistic regression: 1, 2, 3, 4
    • acute ahrf hypoxemic respiratory failure and logistic regression model: 1
    • acute ards respiratory distress syndrome and lmwh heparin: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and lmwh receive: 1
    • acute ards respiratory distress syndrome and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute ards respiratory distress syndrome and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute ards respiratory distress syndrome and low molecular weight lmwh heparin: 1, 2, 3, 4, 5, 6, 7
    • acute care and lmwh heparin: 1, 2